Fatih Mehmet Uckun
#123,420
Most Influential Person Now
Fatih Mehmet Uckun's AcademicInfluence.com Rankings
Fatih Mehmet Uckunengineering Degrees
Engineering
#3971
World Rank
#5119
Historical Rank
Biomedical Engineering
#220
World Rank
#227
Historical Rank

Fatih Mehmet Uckunphilosophy Degrees
Philosophy
#5663
World Rank
#8531
Historical Rank
Logic
#2904
World Rank
#3976
Historical Rank

Download Badge
Engineering Philosophy
Fatih Mehmet Uckun's Degrees
- PhD Biomedical Engineering University of California, Berkeley
- Doctorate Medicine University of California, San Francisco
Why Is Fatih Mehmet Uckun Influential?
(Suggest an Edit or Addition)Fatih Mehmet Uckun's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. (1996) (881)
- Reactive oxygen intermediates activate NF-kappa B in a tyrosine kinase- dependent mechanism and in combination with vanadate activate the p56lck and p59fyn tyrosine kinases in human lymphocytes (1993) (262)
- Dimeric drug polymeric nanoparticles with exceptionally high drug loading and quantitative loading efficiency. (2015) (257)
- Regulation of human B-cell ontogeny. (1990) (255)
- Early response to therapy and outcome in childhood acute lymphoblastic leukemia (1997) (226)
- Expression of dominant-negative and mutant isoforms of the antileukemic transcription factor Ikaros in infant acute lymphoblastic leukemia. (1999) (220)
- Ionizing radiation stimulates unidentified tyrosine-specific protein kinases in human B-lymphocyte precursors, triggering apoptosis and clonogenic cell death. (1992) (190)
- Inhibition of HIV replication by pokeweed antiviral protein targeted to CD4+ cells by monoclonal antibodies (1990) (189)
- Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. (1999) (185)
- Rational Design and Synthesis of a Novel Anti-leukemic Agent Targeting Bruton′s Tyrosine Kinase (BTK), LFM-A13 [α-Cyano-β-Hydroxy-β-Methyl-N-(2,5-Dibromophenyl)Propenamide]* (1999) (176)
- BTK as a Mediator of Radiation-Induced Apoptosis in DT-40 Lymphoma B Cells (1996) (173)
- Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. (1999) (171)
- Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. (1998) (170)
- Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. (1988) (168)
- Clinical development of microbicides for the prevention of HIV infection. (2004) (163)
- Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group. (1998) (150)
- Size-dependent tumor penetration and in vivo efficacy of monodisperse drug-silica nanoconjugates. (2013) (144)
- Expression of aberrantly spliced oncogenic ikaros isoforms in childhood acute lymphoblastic leukemia. (1999) (135)
- Bruton’s Tyrosine Kinase as an Inhibitor of the Fas/CD95 Death-inducing Signaling Complex* (1999) (134)
- Stimulation of protein tyrosine phosphorylation, phosphoinositide turnover, and multiple previously unidentified serine/threonine-specific protein kinases by the Pan-B-cell receptor CD40/Bp50 at discrete developmental stages of human B-cell ontogeny. (1991) (133)
- Tyrosine phosphorylation is a mandatory proximal step in radiation-induced activation of the protein kinase C signaling pathway in human B-lymphocyte precursors (1993) (133)
- Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies (1998) (127)
- Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation. (1998) (125)
- Effect of stereochemistry on the anti-HIV activity of chiral thiourea compounds. (2004) (124)
- Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer Group. (1997) (121)
- Exposure of B-lineage Lymphoid Cells to Low Energy Electromagnetic Fields Stimulates Lyn Kinase (*) (1995) (119)
- Signal transduction through the CD19 receptor during discrete developmental stages of human B-cell ontogeny. (1993) (116)
- Immunobiologic differences between normal and leukemic human B-cell precursors. (1988) (116)
- IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer. (2015) (113)
- Pokeweed antiviral protein: ribosome inactivation and therapeutic applications. (1992) (107)
- Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children's Cancer Group study. (1997) (103)
- Detailed Studies on Expression and Function of CD19 Surface Determinant by Using B43 Monoclonal Antibody and the Clinical Potential of Anti-CD19 Immunotoxins (1988) (103)
- Synthesis, X-ray structure, and anti-leukemic activity of oxovanadium(IV) complexes. (2000) (102)
- Dawn of non-nucleoside inhibitor-based anti-HIV microbicides. (2006) (102)
- Pretransplantation burden of leukemic progenitor cells as a predictor of relapse after bone marrow transplantation for acute lymphoblastic leukemia. (1993) (100)
- Innovative treatment programs against cancer: II. nuclear factor-κB (NF-κB) as a molecular target (1999) (100)
- STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress (2010) (97)
- Leukemic cell growth in SCID mice as a predictor of relapse in high-risk B-lineage acute lymphoblastic leukemia. (1995) (97)
- In vivo radioprotective effects of recombinant human granulocyte colony-stimulating factor in lethally irradiated mice. (1990) (96)
- Crystal Structure of Bruton's Tyrosine Kinase Domain Suggests a Novel Pathway for Activation and Provides Insights into the Molecular Basis of X-linked Agammaglobulinemia* (2001) (95)
- Suppression of Hepatic Inflammation via Systemic siRNA Delivery by Membrane-Disruptive and Endosomolytic Helical Polypeptide Hybrid Nanoparticles. (2016) (92)
- Plant resistance to fungal infection induced by nontoxic pokeweed antiviral protein mutants (1997) (89)
- Metvan: a novel oxovanadium(IV) complex with broad spectrum anticancer activity (2002) (88)
- Biased distribution of chromosomal breakpoints involving the MLL gene in infants versus children and adults with t(4;11) ALL (2001) (88)
- In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor. (1998) (84)
- Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor. (1999) (84)
- In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency. (1992) (84)
- Pokeweed antiviral protein isoforms PAP-I, PAP-II, and PAP-III depurinate RNA of human immunodeficiency virus (HIV)-1. (1999) (83)
- Use of multiple T cell-directed intact ricin immunotoxins for autologous bone marrow transplantation. (1985) (82)
- Bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) as a novel apoptosis-inducing anticancer agent. (2000) (81)
- Supramolecular self-assembled nanoparticles mediate oral delivery of therapeutic TNF-α siRNA against systemic inflammation. (2013) (81)
- Increased efficiency in selective elimination of leukemia cells by a combination of a stable derivative of cyclophosphamide and a human B-cell-specific immunotoxin containing pokeweed antiviral protein. (1985) (80)
- Rational design and synthesis of phenethyl-5-bromopyridyl thiourea derivatives as potent non-nucleoside inhibitors of HIV reverse transcriptase (1998) (77)
- Leukemic B-cell precursors express functional receptors for human interleukin-3. (1989) (77)
- Bruton's tyrosine kinase (BTK) as a dual-function regulator of apoptosis. (1998) (77)
- Interleukin 7 receptor ligation stimulates tyrosine phosphorylation, inositol phospholipid turnover, and clonal proliferation of human B-cell precursors. (1991) (76)
- Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide. (1992) (75)
- Effects of recombinant growth factors on radiation survival of human bone marrow progenitor cells. (1989) (75)
- TXU (Anti-CD7)-Pokeweed Antiviral Protein as a Potent Inhibitor of Human Immunodeficiency Virus (1998) (75)
- Cytotoxic activity of epidermal growth factor-genistein against breast cancer cells. (1998) (74)
- Combined ex vivo treatment with immunotoxins and mafosfamid: a novel immunochemotherapeutic approach for elimination of neoplastic T cells from autologous marrow grafts. (1985) (74)
- Severe combined immunodeficient mouse models of human leukemia. (1996) (74)
- Targeting Janus Kinase 3 in Mast Cells Prevents Immediate Hypersensitivity Reactions and Anaphylaxis* (1999) (71)
- Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: a Children's Cancer Group Study. (1996) (71)
- Transcription Factor STAT5A Is a Substrate of Bruton's Tyrosine Kinase in B Cells* (2001) (71)
- Immunotoxin-mediated elimination of clonogenic tumor cells in the presence of human bone marrow. (1985) (70)
- Stimulation of Src Family Protein-tyrosine Kinases as a Proximal and Mandatory Step for SYK Kinase-dependent Phospholipase Cγ2 Activation in Lymphoma B Cells Exposed to Low Energy Electromagnetic Fields* (1998) (70)
- CD45 cross-linking regulates phospholipase C activation and tyrosine phosphorylation of specific substrates in CD3/Ti-stimulated T cells. (1991) (69)
- Comparative analysis of the in vivo radioprotective effects of recombinant granulocyte colony-stimulating factor (G-CSF), recombinant granulocyte-macrophage CSF, and their combination. (1991) (69)
- Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemia (2001) (69)
- Inducing apoptosis in chemotherapy‐resistant B‐lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti‐apoptotic unfolded protein response signalling network (2011) (69)
- Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice. (2003) (67)
- INTERLEUKIN 2 IMMEDIATELY AFTER AUTOLOGOUS BONE MARROW TRANSPLANTATION FOR ACUTE LYMPHOBLASTIC LEUKEMIA–A PHASE I STUDY (1993) (65)
- Cellular Expression of Antiapoptotic BCL-2 Oncoprotein in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia: A Children's Cancer Group Study (1997) (65)
- Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T‐cell phenotype or other poor prognostic features (1998) (63)
- Molecular genotoxicity profiles of apoptosis-inducing vanadocene complexes. (1999) (63)
- Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds. (2001) (63)
- Apoptosis-inducing vanadocene compounds against human testicular cancer. (2000) (63)
- Bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(I.V.) as a novel antileukemic agent with matrix metalloproteinase inhibitory activity. (2001) (63)
- Novel Thiourea Compounds as Dual-Function Microbicides (2000) (62)
- Autologous bone marrow transplantation in high-risk remission B-lineage acute lymphoblastic leukemia using a cocktail of three monoclonal antibodies (BA-1/CD24, BA-2/CD9, and BA-3/CD10) plus complement and 4-hydroperoxycyclophosphamide for ex vivo bone marrow purging. (1992) (62)
- Structure-based design of a novel synthetic spiroketal pyran as a pharmacophore for the marine natural product spongistatin 1. (2000) (62)
- Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice. (2001) (61)
- Role of Tyrosine Kinases in Induction of the c-junProto-oncogene in Irradiated B-lineage Lymphoid Cells* (1998) (61)
- Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK). (2007) (59)
- Isolation and characterization of pokeweed antiviral protein mutations in Saccharomyces cerevisiae: identification of residues important for toxicity. (1995) (59)
- Structure-based drug design of non-nucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase. (2000) (59)
- Role of a JAK3-dependent Biochemical Signaling Pathway in Platelet Activation and Aggregation* (2001) (58)
- Serine phosphorylation by SYK is critical for nuclear localization and transcription factor function of Ikaros (2012) (56)
- Expression of TEL-AML1 Fusion Transcripts and Response to Induction Therapy in Standard Risk Acute Lymphoblastic Leukemia (2001) (56)
- Establishment of a human t(4;11) leukemia in severe combined immunodeficient mice and successful treatment using anti-CD19 (B43)-pokeweed antiviral protein immunotoxin. (1992) (56)
- Interleukin 7 receptor engagement stimulates tyrosine phosphorylation, inositol phospholipid turnover, proliferation, and selective differentiation to the CD4 lineage by human fetal thymocytes. (1991) (56)
- Ultraviolet radiation rapidly induces tyrosine phosphorylation and calcium signaling in lymphocytes. (1993) (55)
- Vanadocenes as potent anti-proliferative agents disrupting mitotic spindle formation in cancer cells (2001) (55)
- Prophylactic contraceptives for HIV/AIDS. (1999) (55)
- Potent dual anti-HIV and spermicidal activities of novel oxovanadium(V) complexes with thiourea non-nucleoside inhibitors of HIV-1 reverse transcriptase. (2003) (54)
- A Study of the Potential of the Pig as a Model for the Vaginal Irritancy of Benzalkonium Chloride in Comparison to the Nonirritant Microbicide PHI-443 and the Spermicide Vanadocene Dithiocarbamate (2005) (54)
- Calphostin C triggers calcium-dependent apoptosis in human acute lymphoblastic leukemia cells. (1998) (53)
- Allogeneic bone marrow transplantation for acute lymphoblastic leukaemia: risk factors and clinical outcome (1994) (52)
- Structure-based design of N-[2-(1-piperidinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea and N-[2-(1-piperazinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. (1998) (52)
- Aryl phosphate derivatives of bromo-methoxy-azidothymidine are dual-function spermicides with potent anti-human immunodeficiency virus. (1998) (51)
- In Vivo Toxicity, Pharmacokinetics, and Anti-Human Immunodeficiency Virus Activity of Stavudine-5′-(p-Bromophenyl Methoxyalaninyl Phosphate) (Stampidine) in Mice (2002) (51)
- IMMUNOTOXINS FOR THE TREATMENT OF LEUKAEMIA (1993) (51)
- CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemia (2010) (50)
- In vivo antitumor activity of bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) (METVAN [VO(SO4)(Me2-Phen)2]). (2001) (50)
- Biotargeted nanomedicines for cancer: six tenets before you begin. (2013) (50)
- Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus. (1999) (49)
- B-cell growth factor receptor expression and B-cell growth factor response of leukemic B cell precursors and B lineage lymphoid progenitor cells (1987) (48)
- In vivo toxicity and pharmacokinetic features of the janus kinase 3 inhibitor WHI-P131 [4-(4'hydroxyphenyl)-amino-6,7- dimethoxyquinazoline. (1999) (47)
- Stampidine Is a Potent Inhibitor of Zidovudine- and Nucleoside Analog Reverse Transcriptase Inhibitor-Resistant Primary Clinical Human Immunodeficiency Virus Type 1 Isolates with Thymidine Analog Mutations (2002) (46)
- Calpain inhibitor II induces caspase-dependent apoptosis in human acute lymphoblastic leukemia and non-Hodgkin's lymphoma cells as well as some solid tumor cells. (2000) (46)
- Role of tyrosine phosphorylation in radiation-induced activation of c-jun protooncogene in human lymphohematopoietic precursor cells. (1993) (46)
- Enhancing effects of a mono-bromo substitution at the para position of the phenyl moiety on the metabolism and anti-HIV activity of d4T-phenyl methoxyalaninyl phosphate derivatives. (1998) (46)
- N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1. (1999) (45)
- X‐ray crystallographic analysis of the structural basis for the interactions of pokeweed antiviral protein with its active site inhibitor and ribosomal RNA substrate analogs (1999) (45)
- Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3', 5'-dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97). (2000) (45)
- Human t(1;19)(q23;p13) pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency. (1993) (45)
- Structural Requirements for Potent Human Spermicidal Activity of Dual-Function Aryl Phosphate Derivative of Bromo-Methoxy Zidovudine (Compound WHI-07)1 (2000) (44)
- In Vivo Antiretroviral Activity of Stampidine in Chronically Feline Immunodeficiency Virus-Infected Cats (2003) (44)
- Redox-responsive, reversibly-crosslinked thiolated cationic helical polypeptides for efficient siRNA encapsulation and delivery. (2015) (44)
- Poor treatment outcome of Philadelphia chromosome-positive pediatric acute lymphoblastic leukemia despite intensive chemotherapy. (1999) (44)
- Structure-Based Design of Novel Dihydroalkoxybenzyloxopyrimidine Derivatives as Potent Nonnucleoside Inhibitors of the Human Immunodeficiency Virus Reverse Transcriptase (1998) (43)
- Antioxidant function of phenethyl-5-bromo-pyridyl thiourea compounds with potent anti-HIV activity. (2000) (43)
- Toxicity, biological activity, and pharmacokinetics of TXU (anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with human immunodeficiency virus. (1999) (43)
- Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model. (2002) (43)
- Reduced Folate Carrier and Dihydrofolate Reductase Expression in Acute Lymphocytic Leukemia May Predict Outcome: A Children's Cancer Group Study (2003) (42)
- Electromagnetic Field-induced Stimulation of Bruton’s Tyrosine Kinase* (1998) (41)
- Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as nonnucleoside inhibitors of HIV-1 reverse transcriptase. (2000) (40)
- Antigen-independent regulation of cytoplasmic calcium in B cells with a 12-kDa B-cell growth factor and anti-CD19. (1988) (40)
- 4-(3'-Bromo-4'hydroxylphenyl)-amino-6,7-dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells. (1998) (40)
- Role of Janus kinase 3 in mast cell-mediated innate immunity against gram-negative bacteria. (2001) (39)
- Ten-year survival of children with acute lymphoblastic leukemia: A report from the Children's Oncology Group (2008) (39)
- Immunotoxins show rapid entry of diphtheria toxin but not ricin via the T3 antigen. (1986) (39)
- Clinical Significance of Deletions of Chromosome Arm 6q in Childhood Acute Lymphoblastic Leukemia: A Report from the Children's Cancer Group (2000) (39)
- Role of STAT6 in IgE Receptor/FcεRI-Mediated Late Phase Allergic Responses of Mast Cells (2002) (39)
- Innovative treatment programs against cancer. I. Ras oncoprotein as a molecular target. (1998) (38)
- Novel Bruton’s tyrosine kinase inhibitors currently in development (2013) (37)
- Deguanylation of human immunodeficiency virus (HIV-1) RNA by recombinant pokeweed antiviral protein. (1999) (37)
- High-level expression and purification of biologically active recombinant pokeweed antiviral protein. (1999) (37)
- N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1. (1999) (37)
- Combined immunochemotherapy of human solid tumors in nude mice. (1987) (37)
- Highly sensitive liquid chromatography-electrospray mass spectrometry (LC-MS) method for the determination of etoposide levels in human serum and plasma. (2000) (36)
- Synthesis and Structure of Bis(pi-cyclopentadienyl)vanadium(IV) 1,10-Phenanthroline and 2,2'-Bipyridine Compounds and Their Interactions with Artificial Membranes. (1999) (36)
- Metabolism of stavudine-5'-[p-bromophenyl methoxyalaninyl phosphate], stampidine, in mice, dogs, and cats. (2002) (36)
- Spermicidal activity of chelated complexes of bis(cyclopentadienyl)vanadium(IV). (1998) (36)
- Thrombopoietin induces p-selectin expression on platelets and subsequent platelet/leukocyte interactions. (2002) (36)
- Enhanced transmembrane signalling activity of monoclonal antibody heteroconjugates suggests molecular interactions between receptors on the T cell surface. (1989) (35)
- Genetic and biochemical evidence for a critical role of Janus kinase (JAK)-3 in mast cell-mediated type I hypersensitivity reactions. (1999) (34)
- Physical and Functional Interactions between Lyn and p34 Kinases in Irradiated Human B-cell Precursors (*) (1996) (34)
- Human t(4;11)(q21;q23) acute lymphoblastic leukemia in mice with severe combined immunodeficiency. (1994) (34)
- In Vivo Pharmacokinetic Features, Toxicity Profile, and Chemosensitizing Activity of α-Cyano-β-hydroxy-β- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a Novel Antileukemic Agent Targeting Bruton’s Tyrosine Kinase (2002) (34)
- Defective Expression of Bruton's Tyrosine Kinase in Acute Lymphoblastic Leukemia (2003) (34)
- Prognostic significance of the CD10+CD19+CD34+ B-progenitor immunophenotype in children with acute lymphoblastic leukemia: a report from the Children's Cancer Group. (1997) (34)
- In vivo pharmacokinetics and metabolism of anti-human immunodeficiency virus agent D4T-5'-[p-bromophenyl methoxyalaninyl phosphate] (SAMPIDINE) in mice. (2001) (34)
- Ex vivo elimination of lymphoblastic leukemia cells from human marrow by mafosfamid. (1985) (33)
- Structure-Based Design of Non-Nucleoside Reverse Transcriptase Inhibitors of Drug-Resistant Human Immunodeficiency Virus (1999) (33)
- Studies in Humans on the Mechanism of Potent Spermicidal and Apoptosis-Inducing Activities of Vanadocene Complexes (2000) (33)
- Stereocontrolled synthesis of a novel pharmacophore of the tubulin-depolymerizing marine natural product spongistatin (2000) (33)
- Differential substrate recognition capabilities of Janus family protein tyrosine kinases within the interleukin 2 receptor (IL2R) system: Jak3 as a potential molecular target for treatment of leukemias with a hyperactive Jak-Stat signaling machinery. (1999) (33)
- Targeting SYK kinase‐dependent anti‐apoptotic resistance pathway in B‐lineage acute lymphoblastic leukaemia (ALL) cells with a potent SYK inhibitory pentapeptide mimic (2010) (32)
- Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia. (2013) (32)
- Human sperm immobilizing activity of aminophenyl arsenic acid and its N-substituted quinazoline, pyrimidine, and purine derivatives: protective effect of glutathione. (2002) (32)
- 5-Alkyl-2-[(methylthiomethyl)thio]-6-(benzyl)-pyrimidin-4-(1H)-ones as potent non-nucleoside reverse transcriptase inhibitors of S-DABO series. (1998) (32)
- Intrinsic radiation resistance of primary clonogenic blasts from children with newly diagnosed B-cell precursor acute lymphoblastic leukemia. (1993) (32)
- In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase. (2002) (32)
- Targeting Spleen Tyrosine Kinase (Syk) for Treatment of Human Disease (2012) (31)
- Induction of apoptosis in multidrug-resistant and radiation-resistant acute myeloid leukemia cells by a recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor. (1997) (31)
- Targeting Mast Cells in Endometriosis with Janus Kinase 3 Inhibitor, JANEX‐1 (2007) (31)
- Increased hydroxyl radical production and apoptosis in PC12 neuron cells expressing the gain-of-function mutant G93A SOD1 gene. (1999) (31)
- Pre-clinical safety evaluation of novel nucleoside analogue-based dual-function microbicides (WHI-05 and WHI-07). (2002) (31)
- Development and characterization of three recombinant single chain antibody fragments (scFvs) directed against the CD19 antigen. (1995) (30)
- Inhibition of human glioblastoma cell adhesion and invasion by 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) and 4-(3'-bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P154). (1998) (30)
- Structural and biological characterization of a novel spermicidal vanadium(IV) complex: bis(pi-cyclopentadienyl)-N,N-diethyl dithiocarbamato vanadium(IV) tetrafluoro borate, [VCp2(DeDtc)](BF4). (1998) (30)
- Antiretroviral Spermicide WHI-07 Prevents Vaginal and Rectal Transmission of Feline Immunodeficiency Virus in Domestic Cats (2004) (30)
- Regiospecific synthesis, X-ray crystal structure and biological activities of 5-bromothiophenethyl thioureas (2001) (30)
- Active center cleft residues of pokeweed antiviral protein mediate its high-affinity binding to the ribosomal protein L3. (2001) (29)
- G19.4(alpha CD3) x B43(alpha CD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4;11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cells. (1992) (29)
- Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft‐versus‐host disease (GVHD) in a murine allogeneic bone marrow transplantation model (2004) (29)
- Abnormalities of chromosome bands 15q13‐15 in childhood acute lymphoblastic leukemia (2002) (28)
- Repurposing Anti-Malaria Phytomedicine Artemisinin as a COVID-19 Drug (2021) (28)
- Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas (2010) (28)
- Leukemic B-cell precursors constitutively express functional receptors for human interleukin-1. (1989) (28)
- B-cell growth factor receptor expression and B-cell growth factor response of leukemic B cell precursors and B lineage lymphoid progenitor cells. (1987) (28)
- B lymphocyte regulation of human hematopoiesis. (1985) (27)
- Bruton's tyrosine kinase prevents activation of the anti‐apoptotic transcription factor STAT3 and promotes apoptosis in neoplastic B‐cells and B‐cell precursors exposed to oxidative stress (2007) (27)
- CD2 antigen expression on leukemic cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: a Children's Cancer Group study. (1996) (27)
- Modeling and Alanine Scanning Mutagenesis Studies of Recombinant Pokeweed Antiviral Protein* (2000) (27)
- Toxicity and Pharmacokinetics of Stampidine in Mice and Rats (2003) (27)
- Gene expression profiles of infant acute lymphoblastic leukaemia and its prognostically distinct subsets (2010) (27)
- Rational design of potent and selective EGFR tyrosine kinase inhibitors as anticancer agents. (2001) (26)
- Vaginal microbicides and their delivery platforms (2014) (26)
- X-ray structure, solution properties, and biological activity profile of vanadocene(IV) acetylacetonate complex, [VCp2(acac)](CF3SO3): a dual-function anti-cancer agent with anti-angiogenic and anti-mitotic properties (2001) (26)
- Lack of CD24 antigen expression in B-lineage acute lymphoblastic leukemia is associated with intrinsic radiation resistance of primary clonogenic blasts. (1993) (26)
- Bone marrow transplantation for acute lymphocytic leukemia utilizing total body irradiation followed by high doses of cytosine arabinoside: lack of superiority over cyclophosphamide-containing conditioning regimens. (1990) (26)
- Treatment of Post-Bone Marrow Transplant Acute Graft-Versus-Host Disease with a Rationally Designed JAK3 Inhibitor (2002) (26)
- Clinical Pharmacokinetics of the CD19 Receptor‐Directed Tyrosine Kinase Inhibitor B43‐Genistein in Patients with B‐Lineage Lymphoid Malignancies (1999) (26)
- Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity (2010) (26)
- Structure-based design of novel anticancer agents. (2001) (25)
- Targeting JAK3 tyrosine kinase-linked signal transduction pathways with rationally-designed inhibitors. (2007) (25)
- Pharmacokinetic Features and Metabolism of Calphostin C, A Naturally Occurring Perylenequinone with Antileukemic Activity (1999) (25)
- Donor-specific unmodified bone marrow transfusion does not facilitate intestinal engraftment after bowel transplantation in a porcine model. (1997) (25)
- In vitro and in vivo cytotoxicity of an anti-osteosarcoma immunotoxin containing pokeweed antiviral protein. (1995) (25)
- Chemosensitivity of TEL-AML1 Fusion Transcript Positive Acute Lymphoblastic Leukemia Cells (2001) (25)
- Immunotoxins for treatment of leukemia and lymphoma. (1995) (25)
- Preclinical Evaluation of a Dual-Acting Microbicidal Prodrug WHI-07 in Combination with Vanadocene Dithiocarbamate in the Female Reproductive Tract of Rabbit, Pig, and Cat (2007) (25)
- CD4 and CD8 are positive regulators of T cell receptor signal transduction in early T cell differentiation. (1991) (25)
- Novel broad-spectrum thiourea non-nucleoside inhibitors for the prevention of mucosal HIV transmission. (2006) (25)
- GM-144, a novel lipophilic vaginal contraceptive gel-microemulsion (2001) (24)
- Cellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: a Children's Cancer Group Study. (1997) (24)
- D4T-5'-[p-bromophenyl methoxyalaninyl phosphate] as a potent and non-toxic anti-human immunodeficiency virus agent. (1998) (24)
- Innovative treatment programs against cancer: II. Nuclear factor-kappaB (NF-kappaB) as a molecular target. (1999) (24)
- Recipient preconditioning and donor-specific bone marrow infusion in a pig model of total bowel transplantation. (1997) (24)
- High-performance liquid chromatographic methods for the determination of topoisomerase II inhibitors. (2001) (24)
- CD2 antigen expression on leukemic cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: a Children's Cancer Group study (1996) (24)
- CD44 Mediated Nonviral Gene Delivery into Human Embryonic Stem Cells via Hyaluronic-Acid-Coated Nanoparticles. (2016) (24)
- Polo‐like‐kinase 1 (PLK1) as a molecular target to overcome SYK‐mediated resistance of B‐lineage acute lymphoblastic leukaemia cells to oxidative stress (2010) (24)
- X-ray crystallographic analysis of pokeweed antiviral protein-II after reductive methylation of lysine residues. (2000) (24)
- Vinorelbine‐based salvage chemotherapy for therapy‐refractory aggressive leukaemias (2006) (24)
- Effects of Aryl Substituents on the Anti-HIV Activity of the Arylphosphoramidate Derivatives of Stavudine (2002) (24)
- Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase (2006) (24)
- Lack of CD24 antigen expression in B-lineage acute lymphoblastic leukemia is associated with intrinsic radiation resistance of primary clonogenic blasts (1993) (23)
- IMMUNOTOXINS FOR EX VIVO MARROW PURGING IN AUTOLOGOUS BONE MARROW TRANSPLANTATION FOR ACUTE NONLYMPHOCYTIC LEUKEMIA (1988) (23)
- In vitro Activity of Stampidine against Primary Clinical Human Immunodeficiency Virus Isolates (2004) (23)
- Clinical features and treatment outcome of children with biphenotypic CD2+ CD19+ acute lymphoblastic leukemia: a Children's Cancer Group study. (1997) (23)
- Rationally designed anti-mitotic agents with pro-apoptotic activity. (2001) (23)
- Structure-Based Design and Engineering of a Nontoxic Recombinant Pokeweed Antiviral Protein with Potent Anti-Human Immunodeficiency Virus Activity (2003) (22)
- Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review (2021) (22)
- Regulatory Phosphorylation of Ikaros by Bruton's Tyrosine Kinase (2013) (22)
- Chemosensitizing Anti-Cancer Activity of LFM-A13, a Leflunomide Metabolite Analog Targeting Polo-like Kinases (2007) (22)
- Mucosal Toxicity Studies of a Gel Formulation of Native Pokeweed Antiviral Protein (2004) (22)
- Prognostic significance of cytogenetic abnormalities of chromosome arm 12p in childhood acute lymphoblastic leukemia (2000) (22)
- Limitations of the Human‐PBL‐SCID Mouse Model for Vaginal Transmission of HIV‐1 (2007) (22)
- Prognostic significance of T-lineage leukemic cell growth in SCID mice: a Children's Cancer Group study. (1998) (22)
- Signal Transduction through the 1 Integrin Family Surface Adhesion Molecules VLA-4 and VLA-5 of Human B-cell Precursors Activates CD19 Receptor-associated Protein-tyrosine Kinases (*) (1996) (21)
- PHI-443: A Novel Noncontraceptive Broad-Spectrum Anti-Human Immunodeficiency Virus Microbicide1 (2004) (21)
- Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma (2021) (21)
- In vivo Anti-Cancer Activity of a Liposomal Nanoparticle Construct of Multifunctional Tyrosine Kinase Inhibitor 4-(4'-Hydroxyphenyl)-Amino-6,7-Dimethoxyquinazoline (2010) (21)
- Conceival, a novel noncontraceptive vaginal vehicle for lipophilic microbicides (2005) (21)
- EGF-genistein inhibits neointimal hyperplasia after vascular injury in an experimental restenosis model. (2000) (21)
- Increased efficacy in selective elimination of leukemic cell line clonogenic cells by a combination of monoclonal antibodies BA-1, BA-2, BA-3 + complement and mafosfamid (ASTA Z 7557). (1986) (21)
- COVID-19 pandemic: changes in cancer admissions (2020) (21)
- Preclinical and first-in-human phase I clinical evaluation of stampidine, a potent anti-HIV pharmaceutical drug candidate. (2012) (21)
- Anticancer activity of synthetic analogues of the phorboxazoles. (2001) (21)
- Role of the Leukemia-associated Transcription Factor STAT3 in Platelet Physiology (2002) (21)
- CD95 (APO‐1/FAS) deficiency in infant acute lymphoblastic leukemia: detection of novel soluble Fas splice variants (2003) (21)
- Lack of adverse effects on fertility of female cd‐1 mice exposed to repetitive intravaginal gel–microemulsion formulation of a dual‐function anti‐HIV agent: aryl phosphate derivative of bromo‐methoxy‐zidovudine (compound WHI‐07) (2001) (21)
- Cathepsin Inhibition Induces Apoptotic Death in Human Leukemia and Lymphoma Cells (2000) (21)
- Spongistatins as tubulin targeting agents. (2001) (21)
- Thymidine Kinase-Independent Intracellular Delivery of Bioactive Nucleotides by Aryl Phosphate Derivatives of Bromo-Methoxy Zidovudine (Compounds WHI-05 and WHI-07) in Normal Human Female Genital Tract Epithelial Cells and Sperm1 (2001) (21)
- Structural Requirements for Potent Anti-Human Immunodeficiency Virus (HIV) and Sperm-Immobilizing Activities of Cyclohexenyl Thiourea and Urea Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase1 (2002) (20)
- Z-Phe-Gly-NHO-Bz, an inhibitor of cysteine cathepsins, induces apoptosis in human cancer cells. (2000) (20)
- AZT-5′-(p-Bromophenyl Methoxyalaninyl Phosphate) as a Potent and Non-Toxic Anti-Human Immunodeficiency Virus Agent (1999) (20)
- A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia (2019) (20)
- Brutons Tyrosine Kinase as a New Therapeutic Target (2007) (20)
- Role of STAT6 in IgE receptor/FcepsilonRI-mediated late phase allergic responses of mast cells. (2002) (20)
- Substituted heterocyclic thiourea compounds as a new class of anti-allergic agents inhibiting IgE/Fc epsilon RI receptor mediated mast cell leukotriene release. (2003) (20)
- Binding Interactions between the Active Center Cleft of Recombinant Pokeweed Antiviral Protein and the α-Sarcin/Ricin Stem Loop of Ribosomal RNA* (2001) (20)
- Stereochemical influence on lipase-mediated hydrolysis and biological activity of stampidine and other stavudine phosphoramidates. (2005) (20)
- Evaluating dissolution profiles of an anti-HIV agent using ANOVA and non-linear regression models in JMP software. (2003) (20)
- A requirement for protein kinase C inhibition for calcium-triggered apoptosis in acute lymphoblastic leukemia cells. (1999) (20)
- Bioavailability and Pharmacokinetic Features of Etoposide in Childhood Acute Lymphoblastic Leukemia Patients (2001) (20)
- CD22 Exon 12 deletion is a characteristic genetic defect of therapy‐refractory clones in paediatric acute lymphoblastic leukaemia (2012) (20)
- JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia (2011) (20)
- Tyrosine kinases as new molecular targets in treatment of inflammatory disorders and leukemia. (2004) (20)
- The Anti-leukemic Bruto n's Tyrosine Kinase Inhibitor α-cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl) Propenamide (LFM-A13) Prevents Fatal Thromboembolism (2003) (20)
- Anti-T cell immunotoxins containing pokeweed anti-viral protein: potential purging agents for human autologous bone marrow transplantation. (1985) (20)
- Vaginal contraceptive activity of a chelated vanadocene. (2005) (19)
- Structural influence on the solid state intermolecular hydrogen bonding of substituted thioureas (2005) (19)
- SYK as a New Therapeutic Target in B-Cell Precursor Acute Lymphoblastic Leukemia (2014) (19)
- N-[2-(4-Methylphenyl)Ethyl]-N′-[2-(5-Bromopyridyl)]-Thiourea as a Potent Inhibitor of NNRTI-Resistant and Multidrug-Resistant Human Immunodeficiency Virus Type 1 (2000) (19)
- Histamine as an Autocrine Regulator of Leukemic Cell Proliferation (2000) (19)
- Recombinant human CD19L-sTRAIL effectively targets B cell precursor acute lymphoblastic leukemia. (2015) (19)
- Discovery of 2,5-dimethoxy-substituted 5-bromopyridyl thiourea (PHI-236) as a potent broad-spectrum anti-human immunodeficiency virus microbicide. (2005) (19)
- High resolution X-ray structure of potent anti-HIV pokeweed antiviral protein-III. (2003) (19)
- Development and Evaluation of a Thermoreversible Ovule Formulation of Stampidine, a Novel Nonspermicidal Broad-Spectrum Anti-Human Immunodeficiency Virus Microbicide1 (2003) (19)
- Organic phenyl arsonic acid compounds with potent antileukemic activity. (2003) (19)
- Induction of aerobic peroxidation of liposomal membranes by bis(cyclopentadienyl)-vanadium(IV) (acetylacetonate) complexes. (2001) (19)
- Synthesis of Dual Function (5R,6R)- and (5S,6S)-5-Bromo-6-Methoxy-5,6-Dihydro-AZT-5′-(Para-Bromophenyl Methoxyalaninyl Phosphate) as Novel Spermicidal and Anti-HIV Agents (1999) (19)
- Accessory receptors regulate coupling of the T-cell receptor complex to tyrosine kinase activation and mobilization of cytoplasmic calcium in T-lineage acute lymphoblastic leukemia. (1991) (19)
- Apoptosis-inducing oxovanadium(IV) complexes of 1,10-phenanthroline against human ovarian cancer (2000) (19)
- Effect of stereo and regiochemistry towards wild and multidrug resistant HIV-1 virus: viral potency of chiral PETT derivatives. (2004) (18)
- Recurrent or Refractory High-Grade Gliomas Treated by Convection-Enhanced Delivery of a TGFβ2-Targeting RNA Therapeutic: A Post-Hoc Analysis with Long-Term Follow-Up (2019) (18)
- The current status of immunotoxins: an overview of experimental and clinical studies as presented at the Third International Symposium on Immunotoxins. (1993) (18)
- A recombinant fusion toxin targeted to the granulocyte-macrophage colony-stimulating factor receptor. (1997) (18)
- Structural and functional characterization of seven spermicidal vanadium(IV) complexes: potentiation of activity by methyl substitution on the cyclopentadienyl rings. (1999) (18)
- Clinical Impact Potential of Supplemental Nutrients as Adjuncts of Therapy in High-Risk COVID-19 for Obese Patients (2020) (18)
- Reducing the Fatality Rate of COVID-19 by Applying Clinical Insights From Immuno-Oncology and Lung Transplantation (2020) (17)
- Effect of targeted disruption of signal transducer and activator of transcription (Stat)4 and Stat6 genes on the autoimmune diabetes development induced by multiple low doses of streptozotocin. (2005) (17)
- CNS activity of Pokeweed Anti-viral Protein (PAP) in mice infected with Lymphocytic Choriomeningitis Virus (LCMV) (2005) (17)
- Contraceptive activity of a spermicidal aryl phosphate derivative of bromo-methoxy-zidovudine (compound WHI-07) in rabbits. (2003) (17)
- Developmental hierarchy during early human B-cell ontogeny after autologous bone marrow transplantation using autografts depleted of CD19+ B-cell precursors by an anti-CD19 pan-B-cell immunotoxin containing pokeweed antiviral protein (1992) (17)
- Reactive oxygen intermediates activate NF-kappa B in a tyrosine kinase-dependent mechanism and in combination with vanadate activate the p56lck and p59fyn tyrosine kinases in human lymphocytes. (1993) (17)
- Alpha-cyano-beta-hydroxy-beta-methyl-N-[4-(trifluoromethoxy)phenyl] propenamide: an inhibitor of the epidermal growth factor receptor tyrosine kinase with potent cytotoxic activity against breast cancer cells. (1998) (17)
- Evaluation of subchronic (13‐week) and reproductive toxicity potential of intravaginal gel–microemulsion formulation of a dual‐function phenyl phosphate derivative of bromo‐methoxy zidovudine (compound whi‐07) in B6C3F1 mice (2000) (17)
- In vitro and in vivo chemosensitizing activity of LFM-A13, a dual-function inhibitor of Bruton's tyrosine kinase and polo-like kinases, against human leukemic B-cell precursors (2011) (17)
- Rejuveinix Shows a Favorable Clinical Safety Profile in Human Subjects and Exhibits Potent Preclinical Protective Activity in the Lipopolysaccharide-Galactosamine Mouse Model of Acute Respiratory Distress Syndrome and Multi‐Organ Failure (2020) (17)
- Anti-inflammatory activity profile of JANEX-1 in preclinical animal models. (2008) (16)
- Lipid Spheres as Attractive Nanoscale Drug Delivery Platforms for CancerTherapy (2011) (16)
- Two-year toxicity and carcinogenicity studies in B(6)C(3)F(1) mice with 5-bromo-6-methoxy-5,6-dihydro-3'-azidothymidine-5'-(p-bromophenyl) methoxyalaninyl phosphate (WHI-07), a novel anti-HIV and contraceptive agent. (2002) (16)
- Pharmacokinetics and biodistribution of radioimmunoconjugates of anti-CD19 antibody and single-chain Fv for treatment of human B-cell Malignancy (1998) (16)
- A rationally designed nanoparticle for RNA interference therapy in B-lineage lymphoid malignancies (2014) (16)
- Clinical Activity of Folinic Acid in Patients with Chronic Fatigue Syndrome (2006) (16)
- The effects of aromatic and aliphatic maleimide crosslinkers on anti-CD5 ricin immunotoxins. (1989) (15)
- Expression of biologically active recombinant pokeweed antiviral protein in methylotrophic yeast Pichia pastoris. (2000) (15)
- Rational Design and Synthesis of a Novel Anti-leukemic Agent Targeting (1999) (15)
- Structural influence on the anisotropic intermolecular hydrogen bonding in solid state of substituted thioureas: evidence by X-ray crystal structure (2004) (15)
- Stampidine is a potential nonspermicidal broad-spectrum anti-human immunodeficiency virus microbicide. (2004) (15)
- Apoptosis Inducing Novel Anti-Leukemic Agent, Bis(4,7-Dimethyl-1,10 Phenanthroline) Sulfatooxovanadium(IV)[VO(SO4)(Me2-Phen)2] Depolarizes Mitochondrial Membranes (2001) (15)
- Zidampidine, an aryl phosphate derivative of AZT: in vivo pharmacokinetics, metabolism, toxicity, and anti-viral efficacy against hemorrhagic fever caused by Lassa virus. (2005) (15)
- Radiation resistance of primary clonogenic blasts from children with acute lymphoblastic leukemia. (1993) (14)
- Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma (2018) (14)
- Generation and characterization of an anti-CD19 single-chain Fv immunotoxin composed of C-terminal disulfide-linked dgRTA. (1997) (14)
- A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (2021) (14)
- Rational design of an immunoconjugate for selective knock-down of leukemia-specific E2A-PBX1 fusion gene expression in human Pre-B leukemia. (2013) (14)
- Protease-mediated enzymatic hydrolysis and activation of aryl phosphoramidate derivatives of stavudine. (2005) (14)
- CD22ΔE12 as a molecular target for RNAi therapy (2015) (14)
- An improved method for cysteine alkylation (2001) (14)
- Recombinant human CD19‐ligand protein as a potent anti‐leukaemic agent (2011) (14)
- Production of recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system for biotherapy of GMCSF-receptor positive hematologic malignancies. (1998) (14)
- Interactions of Vanadocene(IV)-Chelated Complexes with Artificial Membranes (1998) (14)
- Lipase-mediated stereoselective hydrolysis of stampidine and other phosphoramidate derivatives of stavudine. (2004) (13)
- Bruton's tyrosine kinase as a new therapeutic target. (2007) (13)
- Detection and characterization of human high molecular weight B cell growth factor receptors on leukemic B cells in chronic lymphocytic leukemia. (1989) (13)
- X-Ray structure of glycerol kinase complexed with an ATP analog implies a novel mechanism for the ATP-dependent glycerol phosphorylation by glycerol kinase. (1999) (13)
- Quantitative high-performance liquid chromatography-based detection method for calphostin C, a naturally occurring perylenequinone with potent antileukemic activity. (1999) (13)
- In vitro Anti-HIV Potency of Stampidine Alone and in Combination with Standard Anti-HIV Drugs (2005) (13)
- Quantitative high-performance liquid chromatographic method for pharmacokinetic studies of the potent mast cell inhibitor 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P131). (1999) (13)
- SYK and LYN Mediate B-cell Receptor-independent Calcium-induced Apoptosis in DT-40 Lymphoma B-cells (2002) (13)
- Prognostic significance of B-lineage leukemic cell growth in SCID mice: a Children's Cancer Group Study. (1998) (13)
- CD22ΔE12 as a molecular target for corrective repair using RNA trans-splicing: anti-leukemic activity of a rationally designed RNA trans-splicing molecule. (2015) (13)
- Structure-based design of potent inhibitors of EGF-receptor tyrosine kinase as anti-cancer agents. (1999) (13)
- Development of Polypeptide-based Nanoparticles for Non-viral Delivery of CD22 RNA Trans-splicing Molecule as a New Precision Medicine Candidate Against B-lineage ALL (2015) (13)
- Rational design and synthesis of phenethyl-5-bromopyridyl thiourea derivatives as potent non-nucleoside inhibitors of HIV reserve transcriptase. (1998) (12)
- Phenyl phosphoramidate derivatives of stavudine as anti-HIV agents with potent and selective in-vitro antiviral activity against adenovirus. (2004) (12)
- Mucosal safety of PHI-443 and stampidine as a combination microbicide to prevent genital transmission of HIV-1. (2007) (12)
- Stampidine: a selective oculo-genital microbicide. (2005) (12)
- In vivo Toxicity, Pharmacokinetic Features and Tissue Distribution of N-[2-(2,5-Dimethoxyphenylethyl)]-N’-[2-(5-bromopyridyl)]-thiourea (HI-236), a Potent Non-nucleoside Inhibitor of HIV-1 Reverse Transcriptase (2001) (12)
- Synthesis and metabolism of naphthyl substituted phosphoramidate derivatives of stavudine. (2006) (12)
- Incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia (2013) (12)
- SPIKET and COBRA compounds as novel tubulin modulators with potent anticancer activity. (2000) (12)
- Subchronic (13-week) toxicity studies of intravaginal administration of spermicidal vanadocene acetylacetonato monotriflate in mice. (2002) (12)
- Phase I Study of B43-PAP Immunotoxin in Combination with Standard 4-Drug Induction for Patients with CD 19+ Acute Lymphoblastic Leukemia (ALL) in Relapse, A Children's Cancer Group Study (1999) (12)
- Pharmacokinetics and Biologic Activity of the Novel Mast Cell Inhibitor, 4-(3′-Hydroxyphenyl)-amino-6,7-dimethoxyquinazoline in Mice (2004) (12)
- In vivo Toxicity and Antithrombotic Profile of the Oral Formulation of the Antileukemic Agent, LFM-A13-F (2004) (12)
- Targeting Janus kinase 3 in the treatment of leukemia and inflammatory diseases. (2004) (12)
- Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus (2004) (12)
- A Dual Function Anti-leukemic Agent with Anti-thrombotic Activity (2002) (11)
- Inhibition of mast cell leukotriene release by thiourea derivatives. (2003) (11)
- Effect of alkyl groups on the cellular hydrolysis of stavudine phosphoramidates. (2006) (11)
- CD19-antigen specific nanoscale liposomal formulation of a SYK P-site inhibitor causes apoptotic destruction of human B-precursor leukemia cells. (2014) (11)
- Granulocyte-macrophage colony-stimulating factor receptor-targeted therapy of chemotherapy- and radiation-resistant human myeloid leukemias. (1997) (11)
- Stereoselective synthesis of a versatile intermediate for the total synthesis of mono- and bis-THF containing annonaceous acetogenins (1999) (11)
- COBRA-1, a rationally-designed epoxy-THF containing compound with potent tubulin depolymerizing activity as a novel anticancer agent. (2000) (11)
- Rational drug design of multifunctional phosphoramidate substituted nucleoside analogs. (2004) (11)
- A novel vaginal microbicide containing the rationally designed anti-HIV compound HI-443 (N′-[2-(2-thiophene)ethyl]-N′-[2-(5-bromopyridyl)] thiourea]) (2012) (11)
- CYP1A-mediated metabolism of the Janus kinase-3 inhibitor 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline: structural basis for inactivation by regioselective O-demethylation. (2002) (11)
- Targeting JAK3 and BTK tyrosine kinases with rationally-designed inhibitors. (2006) (11)
- Augmentation of the Antileukemia Potency of Total-Body Irradiation (TBI) by a Novel P-site Inhibitor of Spleen Tyrosine Kinase (SYK) (2010) (10)
- Therapeutic potential of inhibiting Bruton's tyrosine kinase, (BTK). (2004) (10)
- The anti-leukemic Bruton's tyrosine kinase inhibitor alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism. (2003) (10)
- Protein kinase inhibitors against malignant lymphoma (2013) (10)
- Stereochemistry as a Determinant of the Anti-Leukemic Potency of Halopyridyl and Thiazolyl Thiourea Compounds (2007) (10)
- Synthesis of Symmetrical and Asymmetrical Phenethyl Thiourea Compounds as Nonnucleoside Inhibitors of HIV‐1 Reverse Transcriptase (2005) (10)
- Structural influence on the intermolecular/intramolecular hydrogen bonding in solid state of substituted leflunomides : evidence by X-ray crystal structure (2005) (10)
- Erratum to: Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus (2004) (10)
- Liposomal Nanoparticles of a Spleen Tyrosine Kinase P-Site Inhibitor Amplify the Potency of Low Dose Total Body Irradiation Against Aggressive B-Precursor Leukemia and Yield Superior Survival Outcomes in Mice☆ (2015) (9)
- Piperidinylethyl, Phenoxyethyl and Fluoroethyl Bromopyridyl Thiourea Compounds with Potent Anti-HIV Activity (2000) (9)
- IGF 1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer (9)
- Regiospecific Synthesis of 5‐Halo‐substituted Thiophene Pyridyl Thiourea Compounds as Non‐nucleoside Inhibitors of HIV‐1 Reverse Transcriptase (2004) (9)
- Effect of change in nucleoside structure on the activation and antiviral activity of phosphoramidate derivatives. (2005) (9)
- A rationally designed anticancer drug targeting a unique binding cavity of tubulin. (2000) (9)
- Antileukemic Activity and Cellular Metabolism of the Aryl Phosphate Derivative of Bromo-Methoxy Zidovudine (Compound WHI-07) (2005) (9)
- Treatment of BCL-1 murine B-cell leukemia with recombinant cytokines. Comparative analysis of the anti-leukemic potential of interleukin 1 beta (IL-1 beta), interleukin 2 (IL-2), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF alpha), granulocyte colony stimulating factor (G-CSF), granulocyte (1992) (9)
- Inhibitor of HIV-1 reverse transcriptase: N'-(5-bromo-2-pyridyl)-N-[2-(2,5-dimethoxyphenyl)ethyl]thiourea. (1999) (9)
- Stampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDS (2012) (9)
- Therapeutic nanoparticle constructs of a JAK3 tyrosine kinase inhibitor against human B-lineage ALL cells (2010) (9)
- A Previously Unknown Unique Challenge for Inhibitors of SYK ATP-Binding Site: Role of SYK as A Cell Cycle Checkpoint Regulator (2014) (9)
- Cysteine chloromethyl and diazomethyl ketone derivatives with potent anti-leukemic activity. (2000) (9)
- Therapeutic innovations against HIV (2006) (9)
- Allogeneic and autologous bone marrow transplantation for high risk acute lymphoblastic leukemia. (1992) (9)
- Unmet Challenges in HIV Therapy and Potential of Stampidine (2006) (8)
- In vivo Pharmacokinetics and Toxicity Profile of the Anti-HIV Agent Stampidine in Dogs and Feline Immunodeficiency Virus-infected Cats (2006) (8)
- Clinical Potential of Targeting Bruton's Tyrosine Kinase (2008) (8)
- N'-[2-(2-Thiophene)ethyl]-N'-[2-(5-bromopyridyl)]thiourea (HI-443), a Rationally Designed Non-Nucleoside Reverse Transcriptase Inhibitor Compound with Potent Anti-HIV Activity (2007) (8)
- Targeting Solid Tumors With BTK Inhibitors (2021) (8)
- Evaluation of the Pharmacokinetic Features and Tissue Distribution of the Potent Nonnucleoside Inhibitor of HIV-1 Reverse Transcriptase, N-[2-(2-fluorophenethyl)]-N′-[2-(5-bromopyridyl)]-thiourea (HI-240) with an Analytical HPLC Method (1999) (8)
- In vivo radiosensitizing effects of recombinant interleukin 6 on radiation resistant BCL-1 B-lineage leukemia cells in a murine syngeneic bone marrow transplant model system. (1995) (8)
- Paucity of leukemic progenitor cells in the bone marrow of pediatric B-lineage acute lymphoblastic leukemia patients with an isolated extramedullary first relapse. (1999) (8)
- Crystal structure of Bruton's tyrosine kinase domain (2002) (8)
- Low Dose Total Body Irradiation Combined With Recombinant CD19-Ligand × Soluble TRAIL Fusion Protein is Highly Effective Against Radiation-resistant B-precursor Acute Lymphoblastic Leukemia in Mice (2015) (8)
- Primary blasts from infants with acute lymphoblastic leukemia cause overt leukemia in SCID mice. (1998) (8)
- In vivo evaluation of a gel formulation of stampidine, a novel nonspermicidal broad-spectrum anti-HIV microbicide (2003) (8)
- Reactivity of 1,4-didehydronaphthalene toward organic hydrogen atom donors (2000) (8)
- A comparative study of the hydrolysis pathways of substituted aryl phosphoramidate versus aryl thiophosphoramidate derivatives of stavudine. (2004) (8)
- In Vivo Pharmacokinetics and Anti-Anaphylactic Activity of the Novel Mast Cell Inhibitor 4-(4´-Hydroxylphenyl)-Amino-6,7-Dimethoxyquinazoline (WHI-P131) (2001) (8)
- Introduction of a Carbohydrate Moiety into the Structure of Thiourea Compounds Targeting HIV-1 Reverse Transcriptase (2003) (8)
- Tyrosine kinase inhibitors against EGF receptor-positive malignancies. (2001) (8)
- In Vivo Treatment with Monoclonal Antibodies Directed Against CD4 and CD8 Antigens in Miniature Swine (1994) (7)
- Specificity of α-Cyano-β-Hydroxy-β-Methyl-N-[4-(Trifluoromethoxy)Phenyl]-Propenamide as an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase (1999) (7)
- Stereocontrolled synthesis of the tetrahydrofuran unit of annonaceous acetogenins (1998) (7)
- The S-alkyl chain length as a determinant of the anti-leukemic activity of cysteine chloromethyl ketone compounds. (2000) (7)
- Anti-retroviral Activity of GMP-Grade Stampidine against Genotypically and Phenotypically Nucleoside Reverse Transcriptase Inhibitor Resistant Recombinant Human Immunodeficiency Virus (2007) (7)
- Developmental toxicology studies of WHI-07, a novel nucleoside analogue-based dual-function microbicide, administered intravaginally to rabbits. (2003) (7)
- Cell-type-specific cytotoxicity of anti-CD4 and anti-CD8 ricin immunotoxins against human alloreactive T-cell clones. (1989) (7)
- Targeting Mantle Cell Lymphoma with Anti-SYK Nanoparticles. (2012) (7)
- Preclinical Toxicity and Pharmacokinetics of the Bruton's Tyrosine Kinase-Targeting Anti-leukemic Drug Candidate, α-Cyano-β-Hydroxy-β-Methyl-N-(2,5-Dibromophenyl) Propenamide (LFM-A13) (2007) (7)
- mAbs targeting CD20 and other lymphocyte CD markers in lymphoma treatment (2013) (7)
- Residual bone marrow leukemic progenitor cell burden after induction chemotherapy in pediatric patients with acute lymphoblastic leukemia. (2000) (7)
- Selectively targeting TGF-β with Trabedersen/OT-101 in treatment of evolving and mild ards inCOVID-19 (2020) (7)
- Constitutive Function of the Ikaros Transcription Factor in Primary Leukemia Cells from Pediatric Newly Diagnosed High-Risk and Relapsed B-precursor ALL Patients (2013) (7)
- Targeting TGF-b pathway with COVID-19 Drug Candidate ARTIVeda/PulmoHeal Accelerates Recovery from Mild-Moderate COVID-19 (2021) (7)
- Novel monoclonal antibody-based therapies for leukemia (2013) (7)
- Effect of Targeting Janus Kinase 3 on the Development of Intestinal Tumors in the Adenomatous Polyposis Colimin Mouse Model of Familial Adenomatous Polyposis (2007) (7)
- Potency of Stampidine Against Multi-Nucleoside Reverse Transcriptase Inhibitor Resistant Human Immunodeficiency Viruses (2006) (7)
- Absence of Genomic Ikaros/IKZF1 Deletions in Pediatric B-Precursor Acute Lymphoblastic Leukemia. (2013) (7)
- Leflunomide metabolite analogue alpha-cyano-beta-hydroxy-beta-methyl-N-[3-(trifluoromethyl)phenyl]propenamide inhibits IgE/FcepsilonRI receptor-mediated mast cell leukotriene release and allergic asthma in mice. (2001) (7)
- High Resolution X-Ray Structure and Potent Anti-HIV Activity of Recombinant Dianthin Antiviral Protein (2004) (7)
- CD5 antigen-positive B lymphocytes in human B cell ontogeny during fetal development and after autologous bone marrow transplantation. (1993) (7)
- Clinical impact potential of Rejuveinix (RJX) for prevention of fatal acute respiratory distress syndrome (ARDS) and multi-organ failure in COVID-19 patients. (2020) (6)
- Augmentation of Mast Cell Bactericidal Activity by the Anti-leukemic Drug, 4-(3'bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (2002) (6)
- Bone Marrow Leukemic Progenitor Cell Content in Pediatric T-Lineage Acute Lymphoblastic Leukemia Patients with an Isolated Extramedullar First Relapse (2001) (6)
- A 13-Week Subchronic Intravaginal Toxicity Study of the Novel Broad-Spectrum Anti-HIV and Spermicidal Agent, N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea (PHI-346) in Mice (2002) (6)
- Sensitivity of primary clonogenic blasts from acute lymphoblastic leukemia patients to an activated cyclophosphamide, viz., mafosfamide. (1994) (6)
- Anti-cancer Activity Profile of 3’-Azidothymidine 5’- [p-Methoxyphenyl Methoxyalaninyl Phosphate] (Compound 003), a Novel Nucleoside Analog (2004) (6)
- Stampidine as a potent epigenetic silencer of host HIV dependency factor genes in HIV-infected cells. (2012) (6)
- Influence of long-term stability conditions on microbicidal nucleoside prodrug (WHI-07)-loaded gel-microemulsion (2006) (6)
- Expression of a Unique Helios Isoform in Human Leukemia Cells (2002) (6)
- Large-Scale Synthesis and Formulation of GMP-Grade Stampidine, a New Anti-HIV Agent (2006) (6)
- N′-[2-(2-Thiophene)ethyl]-N′-[2′-(5-bromopyridyl)]-thiourea as a Potent Inhibitor of NNI-Resistant and Multidrug-Resistant Human Immunodeficiency Virus-1. (2000) (6)
- A QUANTITATIVE HPLC DETECTION METHOD FOR WHI-P154 [4-(3′-BROMO-4′-HYDROXYLPHENYL)-AMINO-6,7-DIMETHOXYQUINAZOLINE] (1999) (6)
- Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma (2021) (6)
- Optimization of conditions for formation and analysis of anti-CD19 FVS191 single-chain Fv homodimer (scFv')2. (1997) (6)
- Rationale for a randomized, placebo-controlled, Phase 2 study of Rejuveinix (RJX) in COVID-19 patients with acute lung injury and hypoxemic respiratory failure (2020) (6)
- Antigen-independent regulation of cytoplasmic calcium in B cells with a 12-kDa B-cell growth factor and anti-CD 19 ( B-cell activation / signal transduction / indo-1 / leukemic progenitor cells ) (6)
- Identification and targeting of CD22ΔE12 as a molecular RNAi target to overcome drug resistance in high-risk B-lineage leukemias and lymphomas (2018) (6)
- IGF-1 receptor targeted nanoparticles for image-guided therapy of stroma-rich and drug resistant human cancer (2016) (6)
- Evaluation of local tolerance of the antiretroviral spermicide (WHI‐07)‐loaded gel‐microemulsion in the porcine female reproductive tract (2008) (6)
- Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination (2022) (6)
- Synthesis of β‐Fluorophenethyl Halopyridyl Thiourea Compounds as Non‐nucleoside Inhibitors of HIV‐1 Reverse Transcriptase (2004) (6)
- Stat3-Syk Molecular Complex as A Target for Anti-Cancer Nanomedicines (2012) (5)
- Three leflunomide metabolite analogs. (2000) (5)
- 4-[3-Bromo-4-hydroxyphenyl)amino]-6,7-dimethoxyquinazolin-1-ium chloride methanol solvate and 4-[(3-hydroxyphenyl)amino]-6,7-dimethoxy-1-quinazolinium chloride. (2001) (5)
- Distinct in vivo engraftment and growth patterns of t(1;19)+/E2A-PBX1+ and t(9;22)+/BCR-ABL+ human leukemia cells in SCID mice. (1998) (5)
- Development and Evaluation of a Thermoreversible Ovule Formulation of Stampidine, a Novel Nonspermicidal Broad-Spectrum Anti-HIV Microbicide (2003) (5)
- Bone marrow augmentation of kidney allografts can cause graft-versus-host disease in immunosuppressed recipients. (1996) (5)
- Allogeneic and autologous bone marrow transplantation for acute lymphoblastic leukemia. (1990) (5)
- Bone marrow purging with immunotoxins for treatment of T cell acute lymphoblastic leukemia (T-ALL). (1990) (5)
- In vivo Pharmacokinetics, Metabolism, Toxicity, and Anti-HIV Activity of N'-[2-(2-Thiophene)ethyl]-N'-[2-(5-bromopyridyl)]thiourea (HI-443), a Potent Non-nucleoside Inhibitor of HIV Reverse Transcriptase (2007) (5)
- Anti-Inflammatory Activity of 2,4,6-Trihydroxy-α-p-Methoxyphenyl- acetophenone (Compound D-58) (2000) (5)
- Synthesis of a Piceatannol Analog: Replacement of Hydroxy Group with Amide Functionality (2004) (5)
- Stimulation of Bruton's Tyrosine Kinase (BTK) and Inositol 1,4,5-Trisphosphate Production in Leukemia and Lymphoma Cells Exposed to Low Energy Electromagnetic Fields (2000) (5)
- Bis(4,7‐dimethyl and 5‐dinitro‐1,10‐phenanthroline) sulfato‐oxovanadium(IV)‐mediated in vivo male germ cell apoptosis (2001) (4)
- Preclinical toxicity and pharmacokinetics of the Bruton's tyrosine kinase-targeting anti-leukemic drug candidate, alpha-cyano-beta-hydroxy-beta-methyl-N- (2,5-dibromophenyl) propenamide (LFM-A13). (2007) (4)
- Recent advances in anogenital antiretroviral microbicides and multimodal delivery systems. (2012) (4)
- Effects of Recombinant Interleukin‐3 and Recombinant Interleukin‐6 on Radiation Survival of Normal Human Bone Marrow Progenitor Cells (1993) (4)
- Apoptosis-inducing vanadium complexes (2000) (4)
- Recent advances in JAK3 kinase inhibitors. (1999) (4)
- Aryl phosphate derivatives of 3'-deoxythymidine are not potent anti-human immunodeficiency virus agents. (1998) (4)
- Rejection of the colon versus ileum in a pig model of total bowel transplantation. (1996) (4)
- Stampidine: A potential nonspermicidal broad-spectrum anti-HIV microbicide (2003) (4)
- Prevention of UVB-induced skin inflammation, genotoxicity, and photocarcinogenesis in mice by WHI-P131, a dual-function inhibitor of Janus kinase 3 and EGF receptor kinase (2010) (4)
- Anti-proliferative and anti-leukemic activity of DDE46 (compound WHI-07), a novel bromomethoxylated arylphosphate derivative of zidovudine, and related compounds. Studies using human acute lymphoblastic leukemia cells and the zebrafish model. (2005) (4)
- Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes (2020) (4)
- Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436 (2021) (4)
- Five analogs of the active metabolite of leflunomide (1999) (3)
- Prevention of DMBA-induced mammary gland tumors in mice by a dual-function inhibitor of JAK3 and EGF receptor tyrosine kinases (2020) (3)
- Nanoscale Small Interfering RNA Delivery Systems For Personalized Cancer Therapy Research Article (2012) (3)
- Chemoprevention of Colorectal Cancer by Targeting Janus Kinase 3 With a Rationally Designed Small Molecule Inhibitor (2010) (3)
- Recombinant human CD 19 L-sTRAIL effectively targets B cell precursor acute lymphoblastic leukemia (3)
- Improved Oral Bioavailability of Anti-HIV Agent N'-[2-(2-Thiophene)ethyl]-NT-[2-(5-bromopyridyl)]-thiourea (HI-443) in a Novel Lipophilic Formulation (2007) (3)
- Enzymatic hydrolysis of stampidine and other stavudine phosphoramidates in the presence of mammalian proteases. (2005) (3)
- N‐[2‐(1‐Cyclohexenyl)ethyl]‐N′‐[2‐(5‐bromopyridyl)]‐thiourea and N′‐[2‐(1‐Cyclohexenyl)ethyl]‐N′‐[2‐(5‐chloropyridyl)]‐thiourea as Potent Inhibitors of Multidrug‐Resistant Human Immunodeficiency Virus‐1. (2010) (3)
- Preclinical and clinical profile of Emmelle (dextrin-2-sulfate) -- a potential anti-HIV microbicide. (2005) (3)
- Anti-prostate cancer activity of a nanoformulation of the spleen tyrosine kinase (SYK) inhibitor C61 (2020) (3)
- siRNA Carrying Targeted Nanoparticles as a New Class of Rationally- Designed Anti-Cancer Therapeutics (2012) (3)
- Targeting leukemic stem cells with multifunctional bioactive polypeptide nanoparticles. (2015) (3)
- Specificity of a -Cyano- b -Hydroxy- b -Methyl- N -[4-(Trifluoromethoxy)Phenyl]-Propenamide as an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase (1999) (3)
- Anti-inflammatory activity of 2,4, 6-trihydroxy-alpha-p-methoxyphenyl-acetophenone (compound D-58). (2000) (3)
- CD123-Directed Bispecific Antibodies for Targeting MDS Clones and Immunosuppressive Myeloid-Derived Suppressor Cells (MDSC) in High-Risk Adult MDS Patients (2021) (3)
- Nanoscale Small Interfering RNA Delivery Systems For Personalized Cancer Therapy Research Article (2012) (3)
- Large-scale Synthesis of GMP Grade N'-[2-(2-Thiophene)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea (HI-443), a New Anti-HIV Drug Candidate (2007) (2)
- A Rationally Designed Anticancer Drug Targeting a Unique Binding Cavity of Tubulin (2000) (2)
- Alpha-cyano-N-(2,5-dibromophenyl)-beta-hydroxybut-2-enamide. (1999) (2)
- Heterogeneity in leukemia cell populations: A clear rationale for use of combination protocols for ex vivo marrow purging (1985) (2)
- Treating severe COVID-19 in cancer patients (2020) (2)
- Role of PRKCM (PKCμ) in Radiation-Induced Increase of JUN Proto-oncogene mRNA Levels in B-Lineage Lymphoid Cells (2000) (2)
- Ex vivo elimination of neoplastic T-cells from human marrow using an anti-Mr 41,000 protein immunotoxin: Potentiation by ASTA Z 7557 (2004) (2)
- Effects of recombinant human granulocyte-macrophage colony stimulating factor (rhgm-CSF) on radiation survival of normal human bone marrow progenitor cells (1987) (2)
- An Improved Method for Cysteine Alkylation. (2001) (2)
- Genomic Studies of the Spleen Protein Tyrosine Kinase Locus Reveal a Complex Promoter Structure and Several Genetic Variants (2002) (2)
- ATIM-06. TREATMENT OF RECURRENT/REFRACTORY (R/R) ANAPLASTIC ASTROCYTOMA (AA, WHO GRADE 3) PATIENTS WITH ANTI-TGFß2 RNA THERAPEUTIC OT-101 VERSUS TEMOZOLOMIDE IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL (2019) (2)
- Developmental Safety Profile of the Anti-HIV Agent Stampidine in Rabbits (2006) (2)
- 229 Activation of caspases in human t-lineage leukemia cells treated with analogs of leflunomide metabolite (2004) (2)
- Phenyl Phosphoramidate Derivatives of Stavudine as anti‐HIV Agents with Potent and Selective in‐vitro Antiviral Activity Against Adenovirus. (2004) (2)
- 2,4,6-Trihydroxy-&agr;-p-methoxyphenylacetophenone (Compound D-58) Is a Potent Inhibitor of Allergic Reactions (2001) (2)
- An Inhibitor of Janus Kinase 3. 4-(4-Hydroxyphenylamino)-6,7-dimethoxyquinazolin-1-ium Chloride Methanol Solvate. (2001) (2)
- anti‐Cancer Activity Profile of 3′‐Azidothymidine 5′‐[p‐Methoxyphenyl Methoxyalaninyl Phosphate] (Compound 003), a Novel Nucleoside Analogue. (2005) (2)
- Non-clinical safety profile and pharmacodynamics of two formulations of the anti-sepsis drug candidate Rejuveinix (RJX). (2021) (2)
- Developmental Toxicology Studies of WHI-07, a Novel Nucleoside Analogue-Based Dual-Function Microbicide, Administered Intravaginally to Rabbits (2003) (2)
- Role of Defective RNA Processing in the Pathogenesis of Pediatric Diseases (2011) (2)
- Role of Clinical Pharmacodynamics Studies in the Era of Precision Medicines Against Cancer (2018) (2)
- Tyrosine kinases in KMT2A/MLL-rearranged acute leukemias as potential therapeutic targets to overcome cancer drug resistance (2022) (2)
- Stampidine as a Novel Nucleoside Reverse Transcriptase Inhibitor with Potent Anti-HIV Activity (2006) (2)
- Monoclonal Antibody (mAb)-Based Biotherapy Options for B-lineage Non- Hodgkin's Lymphoma (NHL) (2013) (2)
- In silico Molecular Target Validation Demonstrates Transforming Growth Factor Beta 2 is Strongly Expressed in Pediatric Diffuse Intrinsic Pontine Glioma and Glioblastoma Multiforme (2019) (2)
- In vivo Pharmacokinetics and Toxicity of a Novel Hydrophilic Oral Formulation of the Potent Non-Nucleoside Reverse Transcriptase Inhibitor Compound N'-[2-(2-Thiophene)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea (HI-443) (2007) (2)
- KU HAPLOINSUFFIENCY CAUSES A LYMPHOPROLIFERATIVE DISORDER OF IMMATURE T-CELL PRECURSORS DUE TO IKAROS MALFUNCTION. (2013) (2)
- Stereocontrolled Synthesis of a Novel Pharmacophore of the Tubulin‐Depolymerizing Marine Natural Product Spongistatin. (2000) (2)
- Cancer drug resistance in multiple myeloma (2022) (1)
- Overcoming barriers impeding early access of children and adolescents with cancer to emerging new therapeutic platforms and precision medicines (2018) (1)
- Synthesis, Separation and Anti-HIV Activity of Distereoisomers of N-[p-(4-Bromophenyl)-2',3'-didehydro-3'-deoxy-5'-thymidylyl]-L-alanine Methyl Ester (Stampidine) (2006) (1)
- Novel Thiourea Compounds as Dual-Function Anti-HIV and Spermicidal Agents (2000) (1)
- Regulation of Human B Cell Function (1988) (1)
- Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA (2022) (1)
- ERBB1/EGFR and JAK3 Tyrosine Kinases as Potential Therapeutic Targets in High-Risk Multiple Myeloma (2022) (1)
- LOW TEMPERATURE STRUCTURE OF POKEWEED ANTIVIRAL PROTEIN COMPLEXED WITH ADENINE (1999) (1)
- Synthesis of Heterocyclic Thiourea Compounds with Amino Acid Side Chain as Nonnucleoside Inhibitors of HIV‐1 Reverse Transcriptase. (2006) (1)
- Supramolecular Self-Assembled Nanoparticles Mediate Oral Delivery of Therapeutic TNFa TNFa TNFa siRNA against Systemic Inflammation * * (2013) (1)
- Data-Driven identification of chemopreventive agents for breast cancer (2020) (1)
- Abstract 5029: OT-101/Chemotherapy- A novel mechanism of action (MOA) in glioblastoma immunization therapy (2019) (1)
- B-precursor leukemia Nanoscale liposomal formulation of a SYK P-site inhibitor against (2013) (1)
- Regulation of Human B Cell Growth (1989) (1)
- Editorial [Hot Topic:Non-Receptor Tyrosine Kinases as Molecular Targets for Patient Tailored Cancer Therapy (Guest Editors: F.M. Uckun, A. Vassilev and H. Tibbles)] (2007) (1)
- SCID Mouse Models of Human Leukemia and Lymphoma as Tools for New Agent Development (2002) (1)
- Stereoselective Synthesis of a Versatile Intermediate for the Total Synthesis of Mono‐ and Bis‐THF Containing Annonaceous Acetogenins. (1999) (1)
- X-ray structure, solution properties, and biological activity profile of vanadocene(IV) acetylacetonate complex,. (2001) (1)
- Chemopreventive efficacy of stampidine in a murine breast cancer model (2020) (1)
- Development and Characterization of Three Recombinant Single Chain Antibody Fragments ( scFvs ) Directed against the CD 19 Antigen 1 (2006) (1)
- Introduction of a Carbohydrate Moiety into the Structure of Thiourea Compounds Targeting HIV‐1 Reverse Transcriptase. (2003) (1)
- Targeting Human B-Precursor Acute Lymphoblastic Leukemia Cells with Recombinant Human CD19 Ligand (2010) (1)
- Regulatory Reforms Offer Renewed Hope for Pediatric Cancer Patients Who are in Urgent Need for Therapeutic Innovations (2018) (1)
- Non-receptor tyrosine kinases as molecular targets for patient tailored cancer therapy. (2007) (1)
- Site-Specific Enzymatic Activation of the Anti-HIV Agent Stampidine (2006) (1)
- PREVENTION OF ISLET ALLOGRAFT REJECTION IN DIABETIC MICE BY TARGETING JANUS KINASE 3 WITH 4‐(4'‐HYDROXYPHENYL)‐AMINO‐6,7 ‐ DIMETHOXYQUINAZOLINE (WHI‐P131).: Abstract# 1147 (2000) (1)
- Interleukin 3 Stimulation Enhances Tyrosine Phosphorylation and Proliferative Activity of Human Fetal Thymocytes and Leukemic T-cell Precursors at Multiple Developmental Stages of T-cell Ontogeny (1992) (1)
- Augmented Expression of the IL3RA/CD123 Gene in MLL/KMT2A-Rearranged Pediatric AML and Infant ALL (2022) (1)
- Risk and Severity of Cytokine Release Syndrome in Patients with Relapsed/Refractory (R/R) AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436 (2021) (1)
- EARLY DETECTION OF SUBTYPE-SPECIFIC HIV-1 INFECTION USING TRANSCRIPTOMES FROM HOST CELL RESPONSES (2010) (1)
- In vitro and in vivo Pharmacokinetic Features and Metabolism of the Novel Cytotoxic Nucleoside Analog 3’-Azidothymidine 5’- [p-Methoxyphenyl Methoxyalaninyl Phosphate] (Compound 003) (2004) (1)
- disease across the major histocompatibility barrier in mice Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host (2013) (1)
- Organic Phenyl Arsonic Acid Compounds with Potent Antileukemic Activity (2003) (1)
- Recombinant Human CD19 Ligand for Biotherapy of B-lineage Lymphoid Malignancies (2012) (1)
- mAbs targeting RANKL in bone metastasis treatment (2013) (1)
- Large‐Scale Synthesis of GMP Grade α‐Cyano‐β‐hydroxy‐β‐methyl‐N‐ (2,5‐dibromophenyl)propenamide (LFM‐A13), a New Anticancer Drug Candidate. (2007) (1)
- Rejuveinix Reverses Severe Inflammatory Lung Damage in a Mouse Model of Fatal Sepsis (2021) (1)
- Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase. (1999) (1)
- A Degradation Study of a Series of Chloromethyl and Diazomethyl Ketone Anti-leukemic Agents (2002) (1)
- Large-scale Synthesis of GMP Grade α-Cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13), a New Anti-cancer Drug Candidate (2007) (1)
- Three Leflunomide Metabolite Analogues. (2001) (0)
- Subject Index Vol. 201, 2000 (2000) (0)
- allografts in a murine bone marrow transplantation model disease but spares the graft-versus-leukemia function of the bone marrow Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host (2013) (0)
- Non-clinical safety profile and pharmacodynamics of two formulations of the anti-sepsis drug candidate Rejuveinix (2021) (0)
- Therapeuticnanop article constructs of aJ AK3t yrosine kinasei nhibitoragainst humanB-lineage ALL cells (2010) (0)
- Two-year toxicity and carcinogenicity study of the aryl phosphate derivative of bromo-methoxy zidovudine (compound WHI-07), a novel dual-function microbicide (2002) (0)
- 392 Targeting janus kinase 3 with JANEX-1 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice (2004) (0)
- Role of Kinase Inhibitors in Treatment of Lymphoid Malignancies (2013) (0)
- Leukemic T-cell Precursors from T-lineage All Patients Are Characterized by Profound Ku80 Deficiency as well as Functional IK Deficiency with Very Low Ikaros Target Gene Expression Levels (2013) (0)
- Preparation of a nanoscale liposomal CD 22 ΔE 12-siRNA formulation (2015) (0)
- recombinant granulocyte-macrophage CSF, and their combination recombinant granulocyte colony-stimulating factor (G-CSF), Comparative analysis of the in vivo radioprotective effects of (2013) (0)
- Monoclonal Antibodies in Oncology (2013) (0)
- Monotherapy of High-Grade Gliomas with a TGFβ2-Targeting RNA Therapeutic (2020) (0)
- marrow purging complement and 4- hydroperoxycyclophosphamide for ex vivo bone monoclonal antibodies (BA-1/CD24, BA-2/CD9, and BA-3/CD10) plus B-lineage acute lymphoblastic leukemia using a cocktail of three Autologous bone marrow transplantation in high-risk remission (2011) (0)
- HIGH RESOLUTION STRUCTURE OF RECOMBINANT DIANTHIN ANTIVIRAL PROTEIN-POTENT ANTI-HIV AGENT (2004) (0)
- In vivo contraceptive activity of novel dual-function microbicides: aryl phosphate derivatives of bromo-methoxy zidovudine (compounds WHI-05 and WHI-07) (2002) (0)
- Sustained Target Lesion Shrinkage and Favorable Survival Outcome in Radiation and Radio Chemotherapy Resistant High Grade Glioma Treated by Convection Enhanced Delivery of a TGFβ2-Targeting RNA Therapeutic (2020) (0)
- Cysteine Chloromethyl and Diazomethyl Ketone Derivatives with Potent Antileukemic Activity. (2010) (0)
- Study CD2+CD19+ Acute Lymphoblastic Leukemia: A Children's Cancer Group Clinical Features and Treatment Outcome of Children With Biphenotypic (2013) (0)
- Differential effects of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on the radiation sensitivity of normal versus leukemic bone marrow progenitor cell populations. (1997) (0)
- Intronic CD22 Gene Mutations as A Pathogenic Mechanism of Human B-Precursor Leukemia (2010) (0)
- Synthesis of β-Fluorophenethyl Halopyridyl Thiourea Compounds as Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase. (2004) (0)
- Radioimmunotherapy confers extended survival to SCID mice challenged with therapy-refractory human pre-B acute lymphoblastic leukemia (1994) (0)
- Contents Vol. 201, 2000 (2000) (0)
- Abstract LB-365: Unfolded protein response regulator BIP/HSPA5 as a chemoresistance biomarker and molecular target in acute lymphoblastic leukemia (2011) (0)
- Leflunomide Metabolite Analogue &agr;-Cyano-&bgr;-hydroxy-&bgr;-methyl-N-[3-(trifluoromethyl)phenyl] Propenamide Inhibits IgE/FcϵRI Receptor–Mediated Mast Cell Leukotriene Release and Allergic Asthma in Mice (2001) (0)
- STRUCTURE OF POKEWEED ANTIVIRAL PROTEIN COMPLEXED WITH GUANINE (1999) (0)
- Islet allograft survival in signal transducer and activator of transcription factor (STAT)4- and STAT6-deficient mice (2000) (0)
- Stereocontrolled Synthesis of the Tetrahydrofuran Unit of Annonaceous Acetogenins. (1998) (0)
- Regiospecific Synthesis of 5-Halo-Substituted Thiophene Pyridyl Thiourea Compounds as Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase. (2004) (0)
- Structure‐Based Design of a Novel Synthetic Spiroketal Pyran as a Pharmacophore for the Marine Natural Product Spongistatin 1. (2000) (0)
- Wilms’ tumor gene (WT1) is strongly expressed in high-risk subsets of pediatric acute lymphoblastic leukemia (2018) (0)
- Prophylactic administration of a clinically safe low dose of the COVID-19 drug candidate Rejuveinix (RJX) effectively prevents fatal cytokine storm and mitigates inflammatory organ injury in a mouse model of sepsis (2021) (0)
- New Leads for Personalized Medicine in Pediatrics: Targeting Syk for Treatment of Serious Pediatric Illnesses (2012) (0)
- Prevention of development of type 1 diabetes in NOD mice by targeting janus kinase (JAK)3 with 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) (2000) (0)
- Synthesis of Substituted Heterocyclic Thiourea Compounds. (2008) (0)
- ISLET ALLOGRAFT SURVIVAL IN SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION FACTOR (STAT)4‐ AND STAT6‐DEFICIENT MICE.: Abstract# 899 Poster Board #‐Session: P156‐III (2000) (0)
- Rejuveinix Mitigates Sepsis-Associated Oxidative Stress in the Brain of Mice: Clinical Impact Potential in COVID-19 and Nervous System Disorders (2021) (0)
- Radiobiologien! Features of Fresh Leukemic Bone Marrow Progenitor Cells in Acute Lymphoblastic Leukemia1 (2006) (0)
- Acknowledgment to Referees for Dermatology (2000) (0)
- CD22 Exon 12 Deletion as an Independent Predictor of Poor Treatment Outcomes in B-ALL (2023) (0)
- Upregulated Expression of ErbB1 in Diffuse Large B-Cell Lymphoma as a Predictor of Poor Overall Survival Outcome (2023) (0)
- Contraceptive activity of a spermicidal aryl phosphate derivative of bromo-methoxy zidovudine (compound WHI-05) in rabbits. (2011) (0)
- Complexes organometalliques de vanadium (iv) a activite spermicide (1999) (0)
- Reactivity of 1,4‐Didehydronaphthalene Toward Organic Hydrogen Atom Donors. (2000) (0)
- ATIM-03. ANTI-TGFß2 RNA THERAPEUTIC OT-101 INDUCES DURABLE OBJECTIVE RESPONSES IN PATIENTS WITH RECURRENT/REFRACTORY (R/R) GLIOBLASTOMA MULTIFORME (GBM, WHO GRADE 4) OR ANAPLASTIC ASTROCYTOMA (AA, WHO GRADE 3) (2019) (0)
- Immunotoxin Using Anti-CD 19 ( B 43 )-Pokeweed Antiviral Protein Combined Immunodeficient Mice and Successful Treatment Establishment of a Human t ( 4 ; 11 ) Leukemia in Severe Updated (2006) (0)
- Cancer Group Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Association of Chromosome Arm 9p Abnormalities With Adverse Risk in (2012) (0)
- RESPONSE TO TRKA ET AL AND GREAVES ET AL (1999) (0)
- In Vitro and in Vivo Cytotoxicity of an Anti-Osteosarcoma Immunotoxin Containing Pokeweed Antiviral Protein 1 (2006) (0)
- Illinois CNST Annual Nanotechnology Workshop 2010 Lecture 5: Nanoparticles against B–lineage Acute Lymphoblastic Leukemia (2011) (0)
- B- lineage non-Hodgkin's lymphoma cells against clonogenic B-lineage acute lymphoblastic leukemia as well as immunotoxins of human B-cell ontogeny and the efficacy of anti-CD40 Temporal association of CD40 antigen expression with discrete stages (2011) (0)
- SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research (2022) (0)
- Anti-Proliferative and Anti-Leukemic Activity of DDE46 (Compound WHI-07), a Novel Bromomethoxylated Arylphos-phate Derivative of Zidovudine, and Related Compounds (2005) (0)
- Abstract B67: Stroma breaking dual targeted theranostic nanoparticles for image-guided and targeted therapy of pancreatic cancer (2016) (0)
- CD22ΔE12 as a Molecular Target for RNAi Therapy in Mantle Cell Lymphoma (2018) (0)
- Role of Clinical Pharmacokinetics Studies in Contemporary Oncology Drug Development (2018) (0)
- Targeting TGF-beta pathway with COVID-19 Drug Candidate ARTIVeda/PulmoHeal Accelerates Recovery from Mild-Moderate COVID-19 (2021) (0)
- RJX Improves Wound Healing in Diabetic Rats (2022) (0)
- Microbicides for the Prevention of HIV (2014) (0)
- Signal Transduction Through the CD19 Receptor during Developmental Stages of Human B-cell Ontogeny* (2001) (0)
- ATIM-10. CLINICAL PREDICTORS OF RESPONSE FOR RECURRENT/REFRACTORY GLIOBLASTOMA MULTIFORME (GBM) AND ANAPLASTIC ASTROCYTOMA (AA, WHO GRADE III) PATIENTS TREATED WITH THE ANTI-TGFß2 RNA THERAPEUTIC OT-101 (2019) (0)
- human interleukin-1 Leukemic B-cell precursors constitutively express functional receptors for (2012) (0)
- Synthesis of Substituted Terphenyl Derivatives (VIII) (2007) (0)
- LOW TEMPERATURE COMPLEX OF POKEWEED ANTIVIRAL PROTEIN WITH PTEORIC ACID (1999) (0)
- Five Analogues of the Active Metabolite of Leflunomide. (2000) (0)
- CCDC 135712: Experimental Crystal Structure Determination (1999) (0)
- Cancer Group Positive Acute Lymphoblastic Leukemia: A Report From the Children's Clinical Features and Treatment Outcome of Children With Myeloid Antigen (2012) (0)
- Treatment of Childhood T-Lineage Acute Lymphoblastic (1998) (0)
- 1061 Tyrosine kinase inhibitor 2,4,6-trihydroxy-αp-methoxyphenylacetophenone (Compound D-58) Is a potent inhibitor of allergic and inflammatory reactions (2000) (0)
- Monoclonal antibodies in contemporary cancer therapy (2013) (0)
- Pokeweed Antiviral Protein as an Universal Virus Neutralizer (2002) (0)
- Wmmunotoxins for Treatment of Leukemia and LvmDhoma J I (1995) (0)
- Signal transducer and activator of transcription (STAT)4 deficiency, associated with impaired Th1 immune response, reduces sensitivity to multiple low-dose streptozotocin-induced diabetes in STAT4−/− mice (2000) (0)
- Leveraging structure-based rational drug design and nanotechnology to destroy leukemic stem cells (2014) (0)
- Conjugates of antiviral proteins of Pokeweed and monoclonal antibodies. (1990) (0)
- Original research article Vaginal contraceptive activity of a chelated vanadocene (2005) (0)
- RTID-04. CLINICAL POTENTIAL OF TARGETING TRANSFORMING GROWTH FACTOR BETA 2 WITH OT-101 FOR POST-RADIATION CONSOLIDATION IN DIFFUSE INTRINSIC PONTINE GLIOMA (2022) (0)
- Synthesis of a Piceatannol Analogue: Replacement of Hydroxy Group with Amide Functionality. (2004) (0)
- Nanoscale liposomal CD22ΔE12-siRNA formulation as a potent RNAi therapeutic against B-cell precursor acute lymphoblastic leukemia (2014) (0)
- High Intra-Tumor Transforming Growth Factor Beta 2 Level as a Predictor of Poor Treatment Outcomes in Pediatric Diffuse Intrinsic Pontine Glioma (2023) (0)
- Leukemic bone marrow progenitor cells from T-lineage acute lymphoblastic leukemia (ALL) patients are able to repair sublethal radiation damage (1987) (0)
- Phenylarsonic Acid Compounds with Broad-Spectrum and Potent Cytotoxic Activity against Human Cancer Cells (2003) (0)
- Proof of concept for the clinical utility of a convection enhanced delivery platform for immuno-oncology drugs against brain tumors (2019) (0)
- HIGH RESOLUTION STRUCTURE OF RECOMBINANT DIANTHIN ANTIVIRAL PROTEIN-POTENT ANTI-HIV AGENT (COMPLEX WITH CYCLIC AMP) (2004) (0)
- Cancer Group Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Hypodiploidy With Less Than 45 Chromosomes Confers Adverse Risk in (2011) (0)
- Chromosomal Fusion Transcript Expression in the MLL-AF 4 Clinical Significance of (1998) (0)
- Evaluation of the potential of Rejuveinix plus dexamethasone against sepsis (2022) (0)
- Large-scale synthesis of GMP grade alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13), a new anti-cancer drug candidate. (2007) (0)
- 1.6A CRYSTAL STRUCTURE OF POKEWEED ANTIVIRAL PROTEIN-III (PAP-III) WITH METHYLATED LYSINES (2003) (0)
- 344 JANEX-1, a novel anti-cancer agent with anti-thrombotic properties (2004) (0)
- Leflunomide Metabolite Analogue -Cyano- -hydroxy- -methyl-N-[3-(trifluoromethyl)phenyl] Propenamide Inhibits IgE/Fc RI Receptor–Mediated Mast Cell Leukotriene Release and Allergic Asthma in Mice (2001) (0)
- Aryl phosphate derivatives of d4t with anti-HIV effect (1999) (0)
- LOW TEMPERATURE STRUCTURE OF POKEWEED ANTIVIRAL PROTEIN (1999) (0)
- Clinical Potential of Combretastatin A1 Diphosphate for the Treatment of Relapsed Pediatric Acute Myeloid Leukemia (2019) (0)
- Abnormalities o f C hromosome B ands 1 3q12 t o 1 3q14 i n Childhood A cute L ymphoblastic L eukemia (2000) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Fatih Mehmet Uckun?
Fatih Mehmet Uckun is affiliated with the following schools: